Clinical Trial

Orbus Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Study in Newly Diagnosed Glioblastoma

- The Phase 1 Study will Evaluate Eflornithine in Combination with Temozolomide - PALO ALTO, Calif., Sept. 06, 2023 (GLOBE…

9 months ago

Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development…

9 months ago

PharmAla Begins Trading on OTCQB

VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:PMBHF),…

9 months ago

Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th

HAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company…

9 months ago

Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease

– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND…

9 months ago

Awakn Life Sciences Submits Clinical Trial Application for Phase III Trial of AWKN-P001

AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use DisorderToronto,…

9 months ago

Zomedica Closes Acquisition of Structured Monitoring Products Adding Revolutionary VetGuardian Touchless Vital Signs Monitor to Product Portfolio

ANN ARBOR, MI / ACCESSWIRE / September 5, 2023 / Zomedica Corp. (NYSE American:ZOM) ('Zomedica' or the 'Company'), a veterinary…

9 months ago

Sona to Engage with Medical Experts and Payors to Inform Regulatory and Commercialization Strategies for Its ‘THT’ Cancer Therapy

Halifax, Nova Scotia--(Newsfile Corp. - September 5, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")…

9 months ago

NervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at the H.C. Wainwright 25th Annual Global Investment Conference

Vancouver, British Columbia--(Newsfile Corp. - September 5, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech…

9 months ago

Pioneering Stem Cell Nutrition Company Elevating Wellness and Prosperity Together

Approach and Global Impact Solidify Stemtech's Position as Leader in Stem Cell NutritionNAPLES, FL / ACCESSWIRE / September 5, 2023…

9 months ago